Key Highlights

  • MIST reported Q3 total Revenue of US$2,963 thousand, with none a year earlier.
  • Net loss was US$25,796 thousand, or US$0.18 per share, versus US$11,922 thousand.
  • Selling, general and administrative expenses were US$24,232 thousand versus US$7,889 thousand.
  • Cash, cash equivalents and short-term investments were US$145.4 million at September 30, 2026.

MIST filed its Quarterly Report on November 13, 2026, for the three and nine months ended September 30, 2026. Total revenue was US$2,963 thousand, with none in the third quarter of 2025. Product revenue, net, was US$963 thousand, and license and other revenue was US$2,000 thousand. For the nine months, total revenue was US$3,760 thousand, including product revenue of US$1,760 thousand.

The company said CARDAMYST (etripamil) nasal spray for the management of PSVT in the United States became available through U.S. retail pharmacies on January 26, 2026, and its national sales force was deployed in mid-February 2026. It said the license revenue came from a milestone under its license agreement with Everest, due upon NMPA approval of etripamil nasal spray for PSVT in adults.

Launch Spending, Research Costs and Net Loss

Selling, general and administrative expenses were US$24,232 thousand versus US$7,889 thousand, an increase of US$16.3 million, or 207.2%, which the company attributed to additional personnel, professional and other operational costs related to the launch of CARDAMYST. Cost of product sales was US$325 thousand. Research and Development expenses, net of tax credits, were US$3,458 thousand versus US$3,940 thousand, a decrease the company tied to lower outside service costs for Drug Development and research.

Total operating expenses were US$28,015 thousand versus US$11,829 thousand, and the loss from operations was US$(25,052) thousand versus US$(11,829) thousand. Interest income was US$1,438 thousand versus US$874 thousand, and interest expense was US$(2,182) thousand versus US$(967) thousand. Net loss was US$(25,796) thousand, or US$(0.18) per share, versus US$(11,922) thousand, or US$(0.12).

For the nine months, selling, general and administrative expenses were US$67,543 thousand versus US$32,296 thousand, and research and development expenses, net of tax credits, were US$10,191 thousand versus US$12,587 thousand. Net loss was US$(80,476) thousand, or US$(0.59) per share, versus US$(45,649) thousand, or US$(0.60).

Research Spending Detail and Liquidity

By activity, third-quarter clinical costs were US$2,382 thousand versus US$1,718 thousand, drug Manufacturing and formulation costs were US$200 thousand versus US$990 thousand, and regulatory and other costs were US$984 thousand versus US$1,305 thousand, less research tax credits of US$108 thousand. The company recognizes Canadian research and development tax credits as a reduction of research costs.

As of September 30, the company had cash, cash equivalents and short-term investments of US$145.4 million and an accumulated Deficit of US$511.1 million. It described a July 2025 underwritten public offering of 31,500,000 common shares with accompanying Series A and Series B common warrants at a combined price of US$1.50, with net proceeds of US$48.6 million.

Quarter in Review: First Product Sales and Spending Mix

MIST's third quarter combined its first product revenue from CARDAMYST with a US$2,000 thousand license milestone and a sharp rise in selling, general and administrative spending. The company said it earned no product revenue in the 2025 periods, and that revenue is recognized net of allowances for customer discounts, service fees, estimated returns and estimated rebates.